Home>Topics>>Auxilium Pharmaceuticals ([[AUXL]] +0.3%) and strategic partner BioSpecifics ([[BSTC]] +1.3%) both move up after The Journal of Urology publishes its Impress Study, a Phase 3 trial of Xiaflex for the ...
Auxilium Pharmaceuticals ([[AUXL]] +0.3%) and strategic partner BioSpecifics ([[BSTC]] +1.3%) both move up after The Journal of Urology publishes its Impress Study, a Phase 3 trial of Xiaflex for the ...
Auxilium Pharmaceuticals (
AUXL +0.3% ) and strategic partner BioSpecifics ( BSTC +1.3% ) both move up after The Journal of Urology publishes its Impress Study , a Phase 3 trial of Xiaflex for the treatment of Peyronie's disease, which is an excess of inelastic collagen causing penile curvature ...
Read the rest of this article on SeekingAlpha.com: SA Currents